Arcellx, Inc.
ACLX
Pozycja w akcjach
#2777
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Cena akcji
$115.07
Ostatnia synchronizacja: 2026-05-15
Kapitalizacja rynkowa
$6.73B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
32.61%
Kraj
US
Handel Arcellx, Inc. (ACLX)
Kategoria
Healthcare
Zyski dla Arcellx, Inc. (ACLX)
Zyski w Dec 2025 TTM: $-228.87M
Według najnowszych raportów finansowych Arcellx, Inc., obecny zysk firmy wynosi $-228.87M. W roku 2023 firma osiągnęła zysk w wysokości $-70.03M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-188.68M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Arcellx, Inc. od 2018 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-228.87M | 117.39% |
| 2024 | $-105.28M | 50.34% |
| 2023 | $-70.03M | -62.89% |
| 2022 | $-188.68M | 190.41% |
| 2021 | $-64.97M | 102.43% |
| 2020 | $-32.10M | 78.58% |
| 2019 | $-17.97M | 116.32% |
| 2018 | $-8.31M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -2,404.81% |
US
|
|
| $-3.09B | 1,248.83% |
US
|
|
| $-4.02B | 1,654.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -952.31% |
NL
|
